Metrics as of 10/16/2026, 08:35 AM (Berlin time), refresh in progress.
BridgeBio Oncology Therapeutics Stock
BridgeBio Oncology Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Pedro J. Beltran
- Employees
- 88
- Market cap
- $226 M
- IPO
- 12/08/2025
- Web
- bbotx.com
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule…
BridgeBio Oncology Therapeutics stock: price history
1D
-4.4%
1W
-14.8%
1M
-40.8%
6M
-69.8%
YTD
-77.5%
1Y
-75.3%
2Y
-73.1%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~22% weaker price swings than usual
Ask the agents about BridgeBio Oncology Therapeutics
Analyst assessment of BridgeBio Oncology Therapeutics
PRICE TARGET LOW
US$15.00
CONSENSUS
US$19.00
MEDIAN
US$20.00
PRICE TARGET HIGH
US$22.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 11/09/2026
BridgeBio Oncology Therapeutics stock metrics
P/E
-0
P/B
0
EV/EBITDA
-0.95
RETURN ON EQUITY
-17.5%
NET MARGIN
0.0%
DEBT/EQUITY
0.01
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
0.6%
FLOAT SHARES
453,372
AVG. DAILY VOLUME (30D)
707,189
Insider transactions (SEC)
Cobo Marc
Elmelech Idan
Beltran Pedro
Ben Yong
Cobo Marc
Institutional holders
Comparable stocks
Frequently asked questions about BridgeBio Oncology Therapeutics stock
What does BridgeBio Oncology Therapeutics do?
BridgeBio Oncology Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Pedro J. Beltran, the company employs around 88 people.
The IPO was on 12/08/2025; the stock trades on NASDAQ under the ticker BBOT.
What do analysts say about BridgeBio Oncology Therapeutics stock?
8 analysts rate the stock, the consensus is Buy (as of 11/09/2026).
The average price target is US$19.00, ranging from US$15.00 to US$22.00, with a median of US$20.00.
This is an external assessment, not a statement by Market Jury.
When does BridgeBio Oncology Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -22% stronger than usual.
Does BridgeBio Oncology Therapeutics pay a dividend?
No, BridgeBio Oncology Therapeutics currently does not pay a dividend.
Which stocks are comparable to BridgeBio Oncology Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get BridgeBio Oncology Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess BridgeBio Oncology Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.